Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics

Abstract

The adequate absorption of lipids is essential for all mammalian species due to their inability to synthesize some essential fatty acids and fat-soluble vitamins. Chylomicrons (CMs) are large, triglyceride-rich lipoproteins that are produced in intestinal enterocytes in response to fat ingestion, which function to transport the ingested lipids to different tissues. In addition to the contribution of CMs to postprandial lipemia, their remnants, the degradation products following lipolysis by lipoprotein lipase, are linked to cardiovascular disease. In this review, we will focus on the structure-function and metabolism of CMs. Second, we will analyze the impact of gene defects reported to affect CM metabolism and, also, the role of CMs in other pathologies, such as atherothrombotic cardiovascular disease and diabetes mellitus. Third, we will provide an overview of the laboratory tests currently used to study CM disorders, and, finally, we will highlight current treatments in diseases affecting CMs.

Keywords: Abetalipoproteinemia; Atherosclerosis; Chylomicron; Chylomicron retention disease; Enterocyte; Hypobetalipoproteinemia; Laboratory testing; Therapy; Triglyceride; Type I hyperlipidemia; Type V hyperlipidemia.